Hi, what are you looking for?
By Chris Wack
Minerva Neurosciences, Inc. shares were up 25%, to $3.50, after the company said that the U.S. Food and Drug Administration filed its New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
The company said the decision to file the NDA follows its request for formal dispute…
Read the full article here
This article was written by Follow Hi, my names Tyler! While I am currently a student at University of South Carolina well on my...
Watch full video on YouTube
Watch full video on YouTube
This article was written by Follow Buyside analyst covering global stocks on Seeking Alpha since 2018. I’ve been investing personally and professionally across major...
